AR-R17779

AR-R17779
Nazivi
	IUPAC naziv (2S)-2′H-spiro[4-azabiciklo[2.2.2]oktan-2,5'-[1,3]oksazolidin]-2'-on
Identifikacija
CAS broj	178419-47-1 ;
3D model (Jmol)	interaktivna slika;
ChEBI	CHEBI:CHEBI:420311 ;
ChemSpider	4470515 ;
PubChem C ID	5310971;
	SMILES O=C3O[C@]1(CN2CCC1CC2)CN3; ; ; ; ; ;
Svojstva
Hemijska formula	C9H14N2O2
Molarna masa	182,22 g·mol−1
	Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
	verifikuj (šta je ?)
	Reference infokutije

AR-R17779 je lek koji deluje kao potentan i selektivan pun agonist za α7 podtip neurskih nikotinskih acetilholinskih receptora.^[3]^[4] On ispoljava nootropne efekte u životinjskim studijama,^[5]^[6] mada ta dejstva ne zamenjuju dejstva nikotina.^[7] On je nedavno izučavan kao potentan nov tretman za artritis.^[8]

Reference[уреди | уреди извор]

^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^ Mullen, G.; Napier, A.; Balestra, M.; Decory, T.; Hale, G.; Macor, J.; Mack, R.; Loch J, J.; Wu, E. (2000). „(-)-Spiro1-azabicyclo2.2.2octane-3,5'-oxazolidin-2'-one, a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor”. Journal of Medicinal Chemistry. 43 (22): 4045—4050. PMID 11063601. doi:10.1021/jm000249r.
^ Macor, J. .; Mullen, G. .; Verhoest, P. .; Sampognaro, A. .; Shepardson, B. .; Mack, R. . (2004). „A chiral synthesis of (-)-spiro1-azabicyclo2.2.2octane-3,5'- oxazolidin-2'-one: a conformationally restricted analogue of acetylcholine that is a potent and selective alpha7 nicotinic receptor agonist”. The Journal of Organic Chemistry. 69 (19): 6493—6495. PMID 15357617. doi:10.1021/jo049404q.
^ Levin, E. D.; Bettegowda, C.; Blosser, J.; Gordon, J. (1999). „AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats”. Behavioural Pharmacology. 10 (6–7): 675—680. PMID 10780509. doi:10.1097/00008877-199911000-00014.
^ Van Kampen, M.; Selbach, K.; Schneider, R.; Schiegel, E.; Boess, F.; Schreiber, R. (2004). „AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors”. Psychopharmacology. 172 (4): 375—383. PMID 14727003. doi:10.1007/s00213-003-1668-7.
^ Grottick, A. J.; Trube, G.; Corrigall, W. A.; Huwyler, J.; Malherbe, P.; Wyler, R.; Higgins, G. A. (2000). „Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine”. The Journal of Pharmacology and Experimental Therapeutics. 294 (3): 1112—1119. PMID 10945867.
^ Van Maanen, M.; Lebre, M.; Van Der Poll, T.; Larosa, G.; Elbaum, D.; Vervoordeldonk, M.; Tak, P. (2009). „Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice”. Arthritis and rheumatism. 60 (1): 114—122. PMID 19116908. doi:10.1002/art.24177.

Spoljašnje veze[уреди | уреди извор]

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди

[2] Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.

[3] Mullen, G.; Napier, A.; Balestra, M.; Decory, T.; Hale, G.; Macor, J.; Mack, R.; Loch J, J.; Wu, E. (2000). „(-)-Spiro1-azabicyclo2.2.2octane-3,5'-oxazolidin-2'-one, a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor”. Journal of Medicinal Chemistry. 43 (22): 4045—4050. PMID 11063601. doi:10.1021/jm000249r.

[4] Macor, J. .; Mullen, G. .; Verhoest, P. .; Sampognaro, A. .; Shepardson, B. .; Mack, R. . (2004). „A chiral synthesis of (-)-spiro1-azabicyclo2.2.2octane-3,5'- oxazolidin-2'-one: a conformationally restricted analogue of acetylcholine that is a potent and selective alpha7 nicotinic receptor agonist”. The Journal of Organic Chemistry. 69 (19): 6493—6495. PMID 15357617. doi:10.1021/jo049404q.

[5] Levin, E. D.; Bettegowda, C.; Blosser, J.; Gordon, J. (1999). „AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats”. Behavioural Pharmacology. 10 (6–7): 675—680. PMID 10780509. doi:10.1097/00008877-199911000-00014.

[6] Van Kampen, M.; Selbach, K.; Schneider, R.; Schiegel, E.; Boess, F.; Schreiber, R. (2004). „AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors”. Psychopharmacology. 172 (4): 375—383. PMID 14727003. doi:10.1007/s00213-003-1668-7.

[7] Grottick, A. J.; Trube, G.; Corrigall, W. A.; Huwyler, J.; Malherbe, P.; Wyler, R.; Higgins, G. A. (2000). „Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine”. The Journal of Pharmacology and Experimental Therapeutics. 294 (3): 1112—1119. PMID 10945867.

[8] Van Maanen, M.; Lebre, M.; Van Der Poll, T.; Larosa, G.; Elbaum, D.; Vervoordeldonk, M.; Tak, P. (2009). „Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice”. Arthritis and rheumatism. 60 (1): 114—122. PMID 19116908. doi:10.1002/art.24177.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]